                         SEQUENCE LISTING

<110>  INSERM
 
<120>  ANTI-CLAUDIN 1 ANTIBODIES FOR USE IN THE TREATMENT OF COLORECTAL 
       CANCER

<130>  BIO13043 DEL RIO / MC

<160>  8     

<170>  PatentIn version 3.3

<210>  1
<211>  120
<212>  PRT
<213>  Artificial

<220>
<223>  VH

<400>  1

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Ser 
            20                  25                  30          


Gly Met Gln Trp Leu Gln Lys Met Pro Gly Lys Gly Leu Lys Trp Ile 
        35                  40                  45              


Gly Trp Ile Asn Thr His Phe Gly Glu Pro Lys Tyr Ala Glu Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Ser Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Gly Ala Gly Tyr Tyr Gly Ser Arg Tyr Phe Asp Val Trp Gly Ala 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  2
<211>  8
<212>  PRT
<213>  Artificial

<220>
<223>  VH-CDR1

<400>  2

Gly Tyr Thr Phe Thr Thr Ser Gly 
1               5               


<210>  3
<211>  8
<212>  PRT
<213>  Artificial

<220>
<223>  VH-CDR2

<400>  3

Ile Asn Thr His Phe Gly Glu Pro 
1               5               


<210>  4
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  VH-CDR3

<400>  4

Ala Gly Ala Gly Tyr Tyr Gly Ser Arg Tyr Phe Asp Val 
1               5                   10              


<210>  5
<211>  107
<212>  PRT
<213>  Artificial

<220>
<223>  VL

<400>  5

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  6
<211>  6
<212>  PRT
<213>  Artificial

<220>
<223>  VL-CDR1

<400>  6

Gln Asn Val Gly Thr Ala 
1               5       


<210>  7
<211>  3
<212>  PRT
<213>  Artificial

<220>
<223>  VL-CDR2

<400>  7

Ser Ala Ser 
1           


<210>  8
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  VL-CDR3

<400>  8

Gln Gln Tyr Ser Ser Tyr Pro Leu Thr 
1               5                   


